Joseph Catanzaro
Stock Analyst at Piper Sandler
(n/a)
# 3,420
Out of 4,829 analysts
97
Total ratings
n/a
Success rate
-68.15%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Maintains: Overweight | $3.25 → $2.5 | $2.13 | +17.37% | 4 | Apr 14, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $1.93 | +210.88% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $24.17 | +86.18% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $42.50 | +97.67% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $103.82 | +5.95% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $36.98 | +2.76% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $13.74 | +9.17% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $66.58 | -20.40% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $2.75 | +263.64% | 4 | Dec 13, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $57 → $70 | $41.88 | +67.14% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $1.70 | +17.65% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.77 | +973.45% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $4.56 | +316.67% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $1.75 | +757.14% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $3.75 | $0.33 | +1,020.41% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $4.75 | $2.36 | +101.27% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $29.42 | +22.37% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $6.58 | +507.90% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $7.39 | +103.11% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $10.18 | +243.81% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.79 | +473.25% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.20 | +2,400.00% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.49 | +1,242.28% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $0.94 | +961.57% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.31 | +1,274.05% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.36 | +1,738.24% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $7.82 | -77.63% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $23.83 | -16.07% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $0.78 | +92.31% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $0.36 | +2,656.34% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $4.60 | +660.87% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.14 | +5,163.16% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.91 | +518.56% | 3 | Apr 7, 2020 |
CytomX Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $3.25 → $2.5
Current: $2.13
Upside: +17.37%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $1.93
Upside: +210.88%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $24.17
Upside: +86.18%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $42.50
Upside: +97.67%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $103.82
Upside: +5.95%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $36.98
Upside: +2.76%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $13.74
Upside: +9.17%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $66.58
Upside: -20.40%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.75
Upside: +263.64%
Revolution Medicines
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $41.88
Upside: +67.14%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.70
Upside: +17.65%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.77
Upside: +973.45%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $4.56
Upside: +316.67%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $1.75
Upside: +757.14%
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.33
Upside: +1,020.41%
Aug 19, 2024
Maintains: Neutral
Price Target: $6 → $4.75
Current: $2.36
Upside: +101.27%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $29.42
Upside: +22.37%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $6.58
Upside: +507.90%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $7.39
Upside: +103.11%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $10.18
Upside: +243.81%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.79
Upside: +473.25%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.20
Upside: +2,400.00%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.49
Upside: +1,242.28%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $0.94
Upside: +961.57%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $1.31
Upside: +1,274.05%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.36
Upside: +1,738.24%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $7.82
Upside: -77.63%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $23.83
Upside: -16.07%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $0.78
Upside: +92.31%
Mar 10, 2022
Maintains: Overweight
Price Target: $12 → $10
Current: $0.36
Upside: +2,656.34%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $4.60
Upside: +660.87%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.14
Upside: +5,163.16%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.91
Upside: +518.56%